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Abstract
Background: Astaxanthin modulates immune response, inhibits cancer cell growth, reduces bacterial load and
gastric inflammation, and protects against UVA-induced oxidative stress in in vitro and rodent models. Similar
clinical studies in humans are unavailable. Our objective is to study the action of dietary astaxanthin in modulating
immune response, oxidative status and inflammation in young healthy adult female human subjects.
Methods: Participants (averaged 21.5 yr) received 0, 2, or 8 mg astaxanthin (n = 14/diet) daily for 8 wk in a
randomized double-blind, placebo-controlled study. Immune response was assessed on wk 0, 4 and 8, and
tuberculin test performed on wk 8.
Results: Plasma astaxanthin increased (P < 0.01) dose-dependently after 4 or 8 wk of supplementation. Astaxanthin
decreased a DNA damage biomarker after 4 wk but did not affect lipid peroxidation. Plasma C-reactive protein
concentration was lower (P < 0.05) on wk 8 in subjects given 2 mg astaxanthin. Dietary astaxanthin stimulated
mitogen-induced lymphoproliferation, increased natural killer cell cytotoxic activity, and increased total T and B cell
subpopulations, but did not influence populations of Thelper,T cytotoxic or natural killer cells. A higher percentage of
leukocytes expressed the LFA-1 marker in subjects given 2 mg astaxanthin on wk 8. Subjects fed 2 mg astaxanthin
had a higher tuberculin response than unsupplemented subjects. There was no difference in TNF and IL-2
concentrations, but plasma IFN-g and IL-6 increased on wk 8 in subjects given 8 mg astaxanthin.
Conclusion: Therefore, dietary astaxanthin decreases a DNA damage biomarker and acute phase protein, and
enhances immune response in young healthy females.
Introduction
Studies have reported important functions played by
natural carotenoids in regulating immunity and disease
etiology [1,2]. Specifically, interest in the biological
activity of astaxanthin, an oxycarotenoid found in high
amounts in the carapace of crustaceans and in the flesh
of salmon and trout, has increased in recent years. In
vitro studies have demonstrated that astaxanthin is sev-
eral fold more active as a free radical antioxidant than
b-carotene and a-tocopherol [3].
Using a rodent model, we [4] and others [5,6] have
demonstrated that astaxanthin stimulated immune
response in mice. Mice supplemented with astaxanthin
had increased ex vivo splenocyte antibody response to
T-dependent antigens [6], lymphoblastogenic response
and cytotoxic activity [4]. Moreover, these studies also
showed that astaxanthin was consistently more active
than other carotenoids such as b-carotene, lutein and
canthaxanthin.
In addition to immunoregulatory activity, astaxanthin
also inhibited mammary tumor growth. We [7] reported
that dietary astaxanthin inhibited mammary tumor
growth in mice. Astaxanthin has been shown to reduce
bacterial load and gastric inflammation in Helicobacter
pylori-infected mice [5], and to protect against UVA-
induced oxidative stress [8].
Immune cells are particularly sensitive to oxidative
stress due to a high percentage of polyunsaturated fatty
acids in their plasma membranes, and they generally
produce more oxidative products [1]. Overproduction of
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any medium, provided the original work is properly cited.reactive oxygen and nitrogen species can tip the oxidant:
antioxidant balance, resulting in the destruction of cell
membranes, proteins and DNA. Therefore, under condi-
tions of increased oxidative stress (e.g. during disease
states), dietary antioxidants become critical in maintain-
ing a desirable oxidant:antioxidant balance. While stu-
dies on the immunomodulatory role of dietary
astaxanthin have been reported in rodents, similar stu-
dies in humans are not available. We hypothesize that
dietary astaxanthin will act as a potent antioxidative and
anti-inflammatory agent; through these and other
mechanisms, astaxanthin can enhance immune
response. Our objective is to study the possible
immune-enhancing, antioxidative and anti-inflammatory
activity of dietary astaxanthin in humans.
Subjects and methods
Study participants and study design
Free-living healthy female college students with an aver-
age age of 21.5 yr (20.2-22.8 yr) and BMI of 21.6 (16.3-
27.5) were participants in this study. Participants were
recruited from Inha University (Seoul, Korea) through
flyers and emails, and all were native Koreans. Subjects
with a history of diabetes, alcohol abuse, cancer or
smoking were excluded; exclusion criteria also included
those taking antioxidant supplements. Prior to the initia-
tion of dietary supplementation, a three-day dietary
record was obtained from each subject who provided
informed consent. During the study, subjects were
allowed to consume their normal diets but were advised
to refrain from eating astaxanthin-rich foods such as sal-
mon, lobster, and shrimp. Subjects were ranked based
on BMI (age was within a very narrow range) and
groups of 3 participants with similar BNI were randomly
assigned to receive daily: 0 (control; Con), 2 mg (2Asta),
or 8 mg (8Asta) astaxanthin (109 g astaxanthin com-
plex/kg oleoresin concentrate from Haematococcus plu-
vialis, astaZanthin™, La Haye Laboratories Inc.,
Redmond, WA) (n = 14 subjects/diet) for 8 wk in a
double-blind, placebo-controlled study. Astaxanthin was
administered as a softgel capsule taken every morning,
and all softgel capsules were externally identical. Blind-
ing was further ensured by assigning consecutive num-
bers to the dietary treatments and maintaining a master
list until the study was completed. The astaxanthin
complex used in this study came from a supercritical
CO2 extract of Haematococcus pluvialis. Astaxanthin in
the H. pluvialis extract is entirelythe 3S, 3S’ enantiomer,
and is primarily monoesterified with smaller quantities
of diester and free astaxanthin. The astaxanthin complex
also contains small amounts (<15%) of mixed carote-
noids including lutein, b-carotene and canthaxanthin.
To minimize subject-to-subject and assay-to-assay varia-
tion due to different sampling days, blood was drawn
from all 42 subjects on one day for each of wk 0, 4 and
8. Immune function and oxidative status was assessed
within 24 h of blood collection. All procedures were
approved by the Institutional Review Board (IRB #4421)
of Washington State University.
Analytical procedures
HPLC
Astaxanthin content in plasma was analyzed by reverse
phase HPLC (Alliance 2690, Waters, Milford, MA) as pre-
viously described [9]. Trans-b-apo-8’carotenal (Sigma
Chem. Co., St. Louis, MO) was used as the internal stan-
dard. Mobile phase used was acetonitrile:methanol:water,
47:47:16 (v/v/v), and samples were eluted through a 5-μm
spherical C-18 column (3.9 × 150 mm Resolve, Waters,
Milford, MA) at a flow rate of 1.5 mL/min. Absorbance
was monitored at 492 nm on a photo diode array detector.
Lymphoproliferation
The proliferation response of peripheral blood mono-
nuclear cells to phytohemagglutinin (2 and 10 mg/L
final concentration), concanavalin A (2 and 10 mg/L),
and pokeweed mitogen (1 and 5 mg/L) was assessed
using whole blood cultures (to mimic in vivo conditions)
as previously described [10]. Results were calculated as
stimulation index.
Natural killer cell cytotoxic activity
Effector cells (peripheral blood mononuclear cells) and
target (K562) cells were cultured at effector:target ratios
of 5:1 and 10:1 in DMEM (Sigma, St. Louis, MO) con-
taining 100 mL/L fetal bovine serum, 0.1 U/L penicillin,
and 100 g/L streptomycin sulfate. Killing was assessed
using MTT to measure cell viability. The percent of spe-
cific cytotoxicity was calculated as follows:
%/  Specific cytotoxicity 1 OD OD O effector target effector     D D1 target 


  00.
Phenotyping
Populations of total T cells (CD3
+CD19
-), T cytotoxic
cells (Tc; CD3
+CD8
+), T helper cells (Th; CD3
+CD4
+),
B cells (CD3
-CD19
+), and natural killer cells (NK; CD3
-/
CD16
+56
+) were quantitated by dual color flow cytome-
try as previously described [10,11]. Cells were labeled
with monoclonal antibodies conjugated to fluorescein
isothiocyanate (FITC) or phycoerythrin (PE): anti-CD3
w a sc o n j u g a t e dt oF I T C ,a n da n t i - C D 8 ,a n t i - C D 4a n d
anti-CD19 were conjugated to PE (Caltag Laboratories,
Burlingame, CA). In addition, the distribution of the
intercellular adhesion molecule ICAM-1 (CD54
+,B D
Biosciences), and the leukocyte function antigens LFA-1
(CD11a
+, BD Biosciences) and LFA-3 (CD58
+,B DB i o s -
ciences) were measured. A lymphocyte analysis gate and
the antibodies CD45-FITC and CD14-PE (Caltag
Laboratories, Burlingame, CA) were used to help
Park et al. Nutrition & Metabolism 2010, 7:18
http://www.nutritionandmetabolism.com/content/7/1/18
Page 2 of 10distinguish the lymphocytes from other blood cell types.
A total of 2000 gated events were acquired for each
sample and analyzed by flow cytometry (FACScan, BD
Biosciences, San Jose, CA) using the Cell Quest program
(version 3.3).
Tuberculin delayed-type hypersensitivity
Delayed-type hypersensitivity (DTH) response to an
intracutaneous injection of tuberculin (Mono-Vacc Test
O.T., Pasteur Merieux Connaught, France) was assessed
on wk 8. A physician administered the injections and
also measured skin thickness and induration at 0, 24, 48
and 72 h after challenge.
Cytokine production
Plasma samples were analyzed using commercially avail-
able ELISA kits for IL-2 (BD OptEIA™ Set Human IL-2,
BD Biosciences, San Diego, CA), TNFa (BD OptEIA™
Set Human TNF), and IFN-g (BD OptEIA™ Set Human
IFN-g), as well as IL-1b (Amersham Pharmacia Biotech
Inc., Piscataway, NJ) and IL-6 (Amersham Pharmacia
Biotech Inc.).
C-Reactive protein
C-Reactive protein (CRP), a well-established marker of
inflammatory status, was measured in plasma with a
commercially available ELISA (Alpha Diagnostic, San
Antonio, TX).
Oxidative damage to DNA
Oxidative DNA damage was assessed by measuring
plasma 8-hydroxy-2’-deoxyguanosine (8-OHdG) using
competitive ELISA (BIOXYTECH® 8-OHdG-EIA Kit,
OxisResearch, Portland, OR).
Lipid-peroxidation
Plasma concentrations of 8-epi-prostaglandin F2a
(8-isoprostane) were measured by a commercially avail-
able competitive ELISA (8-Isoprostane EIA kit, Cayman
Chemical Company, Ann Arbor, MI).
Statistical analysis
Data were analyzed by repeated measures ANOVA
using the General Linear Model of SAS [12]. Differences
among treatment means were compared by a protected
LSD test and considered different at P < 0.05.
Results
Plasma astaxanthin
Astaxanthin was not detectable in the plasma of any
subjects at wk 0 or in the conrol group at wk 4 or 8.
However, concentrations of astaxanthin in plasma
increased to maximal concentrations by wk 4 in a dose-
dependent manner (Figure 1). Dietary recall showed no
treatment difference in daily dietary intake (Table 1).
Figure 1 Concentrations of plasma astaxanthin in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 wk.
a, bDifferent letters
represent significant treatment differences (P < 0.05) as analyzed by protected LSD test. Values are means; variation is expressed as a
representative overall standard error.
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Proliferation of peripheral blood mononuclear cells was
consistently higher (P < 0.05) when stimulated with
both T cell-dependent (phytohemmaglutinin, concanava-
lin A) and B cell-dependent (pokeweed mitogen) mito-
gens in 8Asta on wk 8 (Figure 2). Both concentrations
of each mitogen showed similar trends whether mito-
gens were low or high concentration. No differences in
response were observed in 2Asta.
NK Cytotoxicity
Higher (P < 0.05) NK cell cytotoxic activity (effector:tar-
get cell ratio of 10:1) was seen in 8Asta but not in 2Asta
by wk 8 (Table 2).
Phenotyping
The population of CD3+ total T cells was higher (P <
0.05) in 2Asta or 8Asta compared to Con on both wk
4 and 8 (Table 2). The percent B cell population was
higher (P < 0.05) only in 2Asta on wk 8 (Table 2). On
the other hand, dietary astaxanthin did not significantly
influence the population of Th, Tc or NK cells or the
ratio of Th:Tc cells (Table 2).
On wk 8, the frequency of cells expressing CD11a+
LFA-1 marker was higher in 2Asta (42%) but not those
given 8Asta (30.6%) compared to Con (32%). Supple-
mental astaxanthin did not have a significant effect on
the expression of the cell surface adhesion molecules
ICAM-1 (CD54) and LFA-3 (CD58) (data not shown).
Tuberculin DTH test
DTH response was maximal at 48 to 72 h post-chal-
lenge (Figure 3). Subjects fed 2Asta had higher (P <
0.05) DTH response than Con, whereas 8Asta did not
show a similar DTH response.
Cytokines
No differences in TNF-a and IL-2 levels were seen in
any treatments (Table 3). By wk 8, IFN-g concentrations
were higher in 8Asta (P < 0.05) (Table 3); IFN-g in
2Asta and Con did not change throughout the study.
Treatment 8Asta also showed an increase (P <0 . 0 5 )i n
IL-6 on wk 8.
C-Reactive protein
The concentration of plasma C-reactive proteins was
lower (P < 0.05) in 2Asta on wk 8 compared to the Con
(Figure 4). However, higher dietary astaxanthin amounts
Table 1 Composition of averaged 3-day dietary recall
within subject treatment groups (n = 14/diet treatment
group) prior to daily supplementation with 0, 2 or 8 mg
astaxanthin
Astaxanthin
0m g 2m g 8m g
Total Kcal (Kcal/d) 1777 1618 1736
Protein (g/d) 64 59 68
Fat (g/d) 54 49 52
CHO (g/d) 258 238 254
a-Carotene (μg/d) 457 527 567
b-Carotene (μg/d) 1813 1664 1773
b-Cryptoxanthin (μg/d) 61 81 38
Lutein & Zeaxanthin (μg/d) 610 490 338
Lycopene (μg/d) 2067 2327 1133
There were no differences between groups, as determined by T test.
Values are means of 3-day dietary recalls.
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Figure 2 Lymphocyte proliferation induced with
phytohemagglutinin, concanavalin A and pokeweed mitogen
in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 wk.
Responses to high concentrations of mitogens (10 mg
phytohemmaglutinin/L, 10 mg concanavalin A/L and 5 mg
pokeweed mitogen/L final concentration) are shown.
a, bDifferent
letters represent significant treatment differences (P < 0.05) as
analyzed by protected LSD test. Values are means ± SEM.
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Page 4 of 10did not influence the concentration of this acute phase
protein.
DNA Damage
Concentrations of 8-OHdG were dramatically lower
(P < 0.01) as early as wk 4 in 2Asta and 8Asta (Figure
5). DNA damage observed with 2Asta was not further
decreased in the group fed higher dietary astaxanthin
(8Asta).
Lipid Peroxidation
Dietary astaxanthin did not significantly influence con-
centrations of plasma 8-isoprostane at all periods stu-
died. The overall mean concentration of 8-isoprostane
was 30.8 ± 0.4 pg/mL across all treatments.
Discussion
While the biological action of astaxanthin has been
reported in both in vitro and in vivo studies, these have
mainly used rodents and in vitro m o d e l s .T h i si st h e
first comprehensive study to examine the action of diet-
ary astaxanthin in regulating immune response, oxida-
tive damage and inflammation in humans. Dietary
astaxanthin enhanced both cell-mediated and humoral
immune responses in young healthy feamles. The
immune markers significantly enhanced by feeding
astaxanthin included T cell and B cell mitogen-induced
lymphocyte proliferation, NK cell cytotoxic activity,
IFN-g and IL-6 production, and LFA-1 expression.
Enhancement of these ex vivo immune markers corre-
sponded with increased number of circulating total T
and B cells. In addition, subjects given astaxanthin also
showed an enhanced tuberculin DTH response, a reli-
able clinical test to assess in vivo Tc e l lf u n c t i o n .A l lo f
Table 2 Immune cell response following daily
supplementation with 0, 2 or 8 mg astaxanthin after
0, 4 and 8 wk
Treatment Wk 0 Wk 4 Wk 8
Total T cells (%)
0 mg 65.9 ± 2.1 64.4 ± 1.9
b 70.6 ± 1.5
b
2 mg 69.5 ± 1.4 69.6 ± 1.5
a 75.7 ± 1.6
a
8 mg 67.2 ± 2.2 69.6 ± 1.8
a 74.3 ± 1.8
ab
Total Th cells (%)
0 mg 35.3 ± 1.5 36.3 ± 1.7 39.6 ± 1.4
2 mg 35.3 ± 1.8 36.0 ± 1.9 39.7 ± 2.0
8 mg 35.2 ± 1.5 34.3 ± 1.4 38.4 ± 1.2
Total Tc cells (%)
0 mg 26.7 ± 1.4 26.1 ± 1.2 28.4 ± 1.4
2 mg 28.2 ± 1.9 27.6 ± 1.9 28.7 ± 1.6
8 mg 28.4 ± 1.6 28.3 ± 1.6 28.8 ± 2.1
Th:Tc ratio cells
0 mg 1.35 ± 0.07 1.43 ± 0.09 1.48 ± 0.10
2 mg 1.31 ± 0.15 1.35 ± 0.16 1.46 ± 0.15
8 mg 1.31 ± 0.13 1.29 ± 0.13 1.37 ± 0.14
Total B cells (%)
0 mg 11.4 ± 0.9 11.1 ± 0.5 10.7 ± 0.5
b
2 mg 13.1 ± 1.1 12.7 ± 1.2 13.1 ± 0.5
a
8 mg 13.3 ± 1.4 11.9 ± 0.7 11.1 ± 0.3
ab
Total NK cells (%)
0 mg 13.7 ± 0.9 12.6 ± 1.2 10.6 ± 0.8
2 mg 12.5 ± 1.0 13.1 ± 1.9 12.6 ± 1.5
8 mg 13.4 ± 1.1 15.6 ± 1.4 13.1 ± 1.4
NK cytotoxic activity(% lysis)
0 mg 51.5 ± 4.4 51.0 ± 2.5 57.8 ± 2.7
b
2 mg 58.2 ± 3.8 54.4 ± 2.9 57.1 ± 2.6
b
8 mg 56.1 ± 3.1 54.3 ± 1.9 67.9 ± 3.0
a
a, bDifferent letters represent significant treatment differences (P < 0.05) as
analyzed by ANOVA. Values are means ± SEM.
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Figure 3 Delayed-type hypersensitivity tuberculin test in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 wk.
a, bDifferent
letters represent significant treatment differences (P < 0.05) as analyzed by protected LSD test. Values are means ± overall standard error.
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wk of supplementation following a cutaneous tuberculin
injection.
Modulatory actions of astaxanthin on immune
response have been demonstrated in both in vitro and
in vivo studies. We previously reported higher mitogen-
induced splenocyte proliferation in mice [4], dogs [13]
and cats [14] fed astaxanthin. Astaxanthin stimulated
cell proliferation of murine splenocytes and thymocytes
in vitro [15]. Others have shown that astaxanthin
increased cytotoxic T lymphocyte activity in mice [16]
and inhibited stress-induced suppression of NK cell
activity [17]. In this study, astaxanthin heightened NK
cell cytotoxic activity. Natural killer cells serve in an
immuno-surveillance capacity against tumors and virus-
infected cells; therefore, astaxanthin may play a role in
cancer etiology. Patients with Chediak-Higashi syn-
drome, a disorder associated with defective NK cell
function, are indeed more susceptible to tumor
formation.
Flow cytometry data showed higher subpopulations of
total T and B cells. Activated T cells and NK cells pro-
duce IFN-g, which is involved in immune-regulation, B
cell differentiation, and antiviral activity. IFN-g produc-
tion was higher in subjects supplemented with astax-
anthin, similar to the response in mice given
astaxanthin [16]. Splenocytes of tumor-bearing mice fed
lutein also had higher IFN-g expression, and these
changes paralleled the inhibitory action of lutein against
tumor growth [18]. Astaxanthin decreased bacterial load
and gastric inflammation in mice infected with Helico-
bacter pylori by shifting the T-lymphocyte response
from a Th1 response dominated by IFN-g to a Th1/Th2
response dominated by IFN-g and IL-4 [5]. Modulation
of the humoral immune response also occurs; astax-
anthin increased antibody production in mouse spleno-
cytes [19], partially restored humoral immune response
in old mice [6], enhanced immunoglobulin production
in response to T-dependent stimuli in human blood
cells [20] and induced production of polyclonal
Table 3 Cytokine response following daily
supplementation with 0, 2 or 8 mg astaxanthin after
0, 4 and 8 wk
Treatment Wk 0 Wk 4 Wk 8
TNF-a (pg/mL); Overall SE = 0.43
0 mg 1.14 1.63 1.43
2 mg 0.80 1.13 1.44
8 mg 1.51 2.15 2.60
IFN-g (pg/mL); Overall SE = 0.34
0 mg 5.85 4.47 4.68
b
2 mg 4.87 4.26 5.00
b
8 mg 4.67 6.23 9.55
a
IL-6 (pg/mL); Overall SE = 2.9
0 mg 10.5 12.7 13.6
b
2 mg 10.0 11.5 8.7
b
8 mg 11.5 12.4 25.2
a
IL-2 (pg/mL); Overall SE = 0.10
0 mg 8.61 8.04 7.74
2 mg 5.09 4.67 4.46
8 mg 4.91 4.01 3.90
a, bDifferent letters represent significant treatment differences (P < 0.05) as
analyzed by ANOVA. Values are means; variation is expressed as a
representative overall standard error.
Figure 4 Plasma concentrations of plasma C-reactive protein in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 wk.
a, bDifferent letters represent significant treatment differences (P < 0.05) as analyzed by protected LSD test. Values are means ± overall standard
error.
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Page 6 of 10antibodies G and M in murine spleen cells [15]. The
present study suggests that the higher antibody produc-
tion may be due to an increase in B cell number.
The skin tuberculin test is a reliable clinical test to
assess in vivo T cell function. This study shows that
subjects given astaxanthin had a heightened DTH
response, which is also seen in dogs [13] and cats fed
astaxanthin [14], b-carotene [10,14] and lutein [21,22].
Leukocyte function antigens (LFA) mediate intercellular
adhesion between leukocytes and other cells in an anti-
gen non-specific fashion. LFA-1 is a b2-integrin
expressed on leukocytes involved in the migration of
lymphocytes, monocytes and neutrophils. LFA-1 binds
to ICAM-1 and ICAM-2 expressed on vascular endothe-
lium, and controls lymphocyte migration into inflamma-
tory sites. Endothelial expression of ICAM-1 is inducible
while ICAM-2 is constitutive. Therefore, the heightened
DTH response in this study is likely due to an increased
expression of LFA-1 but not ICAM.
Dietary astaxanthin dramatically decreased one DNA
damage biomarker (plasma 8-OHdG), and this protec-
tive effect was observed by wk 4 of feeding. Maximal
response was observed with the lower 2 mg astaxanthin
dose. In addition, subjects fed 2 mg astaxanthin also
showed lower plasma C-reactive protein concentrations,
demonstrating the anti-inflammatory action of astax-
anthin in humans. Immune cells are particularly sensi-
tive to membrane damage by free radicals. Reactive
oxygen species (ROS) are produced via the mitochondria
electron transport system during ATP production,
xanthine oxidase and phagocytes [23,24]. In fact, cumu-
lative oxidative damage to the mitochondria is consid-
ered the main culprit of cell senescence which in turn is
responsible for aging and the development of age-related
chronic diseases [25]. The ROS can induce redox-sensi-
tive transcription factors such as NFkB and AP-1, which
regulate genes controlling production of chemokines,
inflammatory cytokines, and adhesion molecules which
stimulate phagocytic infiltration [26]. Conversely, astax-
anthin, acting as a potent antioxidant, can inhibit ROS-
induced production of these transcription factors,
thereby decreasing inflammation. Indeed, astaxanthin
attenuated exercise-induced neutrophil infiltration and
subsequent delayed-onset damage to the gastronemius
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Page 7 of 10and heart muscle in mice [26]. Astaxanthin is reported
to be approximately 100 fold more protective than
lutein and b-carotene against UVA-induced oxidative
stress in vitro [8].
Reactive nitrogen species also play an important role
in inflammation. As with ROS, astaxanthin has been
reported to decrease the production of nitric oxide
( N O )a n di N O Sa c t i v i t yi nam o u s em a c r o p h a g ec e l l
line, resulting in the inhibition of COX which down-reg-
ulates the production of PGE2 and TNF-a [27]. TNF-a
is a pleiotropic cytokine produced by activated macro-
phages and monocytes, and has nonspecific resistance
against various infectious agents. Similarly, Lee et al.
[28] reported that astaxanthin suppressed serum NO,
TNFa and IL-1b in mice injected with lipopolysacchar-
ide. The TNF-a and IL-1 cascade activates p38 MAPK,
thus promoting proinflammatory gene expression and
cytokine production. Therefore, in this study, astax-
anthin exerted its anti-inflammatory action by inhibiting
reactive oxygen and nitrogen species.
Why dietary astaxanthin did not reduce lipid peroxi-
dation is unclear. Astaxanthin has been shown to be
one of the most effective antioxidants against lipid per-
oxidation and oxidative stress in in vitro and in vivo sys-
tems [3,29]. Humans given 1.8 to 21.6 mg astaxanthin
daily for 14 d increased the lag time for LDL oxidation
[30]. Astaxanthin is as effective as a-tocopherol in inhi-
biting radical-initiated lipid peroxidation in rat liver
microsomes [31], and is 100 times more active than a-
tocopherol in protecting the rat mitochondria against
Fe
2+-catalyzed lipid peroxidation in vivo and in vitro [3].
The potent antioxidant activity of astaxanthin is likely
due to the presence of a keto- and a hydroxyl group on
each end of its molecule. This structural property effec-
tively rigidifies cell membranes, thereby limiting the
penetration of lipoperoxidation promoters across the
lipid bilayer [32]. The isoprostane methodology used in
this study lacks sensitivity and accuracy; this may
account for the lack of a significant effect seen in this
study.
Taken together, the immunomodulatory, antioxidative
and anti-inflammatory activity of astaxanthin will likely
influence the etiology of cancer and inflammatory diseases.
Astaxanthin was more active than b-carotene, lutein and
canthaxanthin in inhibiting mammary tumor growth in
mice [7]. Others have reported that astaxanthin protected
against carcinogenesis of the urinary bladder [33],
decreased cancerous growth of the mouth [34], and
decreased the number and size of liver preneoplastic foci
[35] in rodents. Astaxanthin, as an algal extract, protected
UVA-induced DNA damage in human skin fibroblasts
(IBR-3), melanocytes (HEMAc) and intestinal CaCo2 cells
[36]. In addition, astaxanthin ameliorated other oxidative
stress-induced inflammatory diseases such as diabetic
nephropathy in diabetic mice [37], lipopolysaccharide-
induced uveitis in rats [27], and exercise-induced skeletal
and cardiac muscle damage in mice [26].
The polar ends if the astaxanthin structure allows it
span biological membranes; this transmembrane align-
ment allows astaxanthin to preserve the membrane
structure [38], decrease membrane fluidity [39], and
function as an antioxidant [40]. These and other
mechanisms may explain the antioxidative, anti-inflam-
matory and immune-modulatory action of astaxanthin.
In this study, plasma concentrations of astaxanthin
in subjects given 2 or 8 mg astaxanthin daily for 4 wk
increased to 0.09 to 0.13 μmol/L, with no further
increase observed at 8 wk. These plasma concentra-
tions are lower than that reported by Osterlie et al.
[41] who showed maximal concentrations of 1.3 mg/L
(2.28 μmol/L) in subjects administered a single oral
dose of 100 mg astaxanthin. The difference in plasma
concentrations in the two human studies is expected,
d u et od i f f e r e n c e si nt h ed o s ea n dl e n g t ho fa s t a x -
anthin administration; however, the two studies also
used different sources of astaxanthin and different sub-
ject gender and age. Most of the astaxanthin was
found in the VLDL chylomicra, with lesser amounts in
the LDL and HDL [41]. While the stereoisomer form
of astaxanthin was not identified in this study, Osterlie
et al. [41] reported a preferential uptake of the Z-iso-
mers as compared to the all-E-astaxanthin. Astax-
anthin used in the present study is from
Haematococcus pluvialis and exists primarily in an
esterified 3S, 3’S stereoisomer while synthetic astax-
anthin [41] is primarily the 3R, 3’S form. The amount
of supplemental astaxanthin used in this study is
achievable through diet means. For instance, the astax-
anthin content of salmon flesh ranges from 3 to 37
mg/kg [42,43]; therefore, a 200-g serving of salmon
provides approximately 1 to 7 mg astaxanthin. Wild
salmon contains the 3S, 3S’ form of astaxanthin almost
exclusively. The 3R, 3R’ form is found rarely in nature
but does exist in some crustaceans such as in Krill. In
healthy humans, 6 mg astaxanthin from H. pluvialis
algal extract can be safely consumed [44].
Overall, this study shows that dietary astaxanthin
enhanced immune response, and decreased a DNA oxi-
dative damage biomarker and inflammation in young
healthy females. It is the initial scope of the study to
focus on a narrow population with regards to age, gen-
der and race; however, antioxidants generally show
greater physiologic modulation under excess amounts of
oxidative stress, in immuno-compromised individuals,
and with longer feeding periods. These likely explain the
lack of efficacy in certain response measures studied.
Future studies with astaxanthin administration will
include these parameters. However, our present study
Park et al. Nutrition & Metabolism 2010, 7:18
http://www.nutritionandmetabolism.com/content/7/1/18
Page 8 of 10suggests astaxanthin to be a bioactive natural carotenoid
that may be important to human health.
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